拉米夫定联合左旋咪唑搽剂治疗慢性乙型肝炎的临床观察  

Comparison of the effects between LAM and LAM joining Lot.Levamisole for treating the patients with chronic hepatitis B

作　　者：欧雄书 黎署光 

机构地区：[1]广东省新兴县人民医院,广东新兴527400

出　　处：《全科医学临床与教育》2004年第3期165-166,共2页Clinical Education of General Practice

摘　　要：目的观察慢性乙型肝炎患者拉米夫定(LAM)与拉米夫定联合左旋咪唑搽剂近期疗效及远期疗效。方法HBVDNA和HBeAg均阳性的100例慢性乙型肝炎患者按1:1比例分成两个不同的治疗组 ,联合治疗组 :用左旋咪唑搽剂1支每3天涂皮肤及口服LAM100mg/d共12个月。LAM组 :口服LAM100mg/d共12个月。定期检测HBVDNA、ALT、两对半。结果治疗结束时 ,HBVDNA阴转率 ,联合组为94.00% ,LAM组为86.00%。HBeAg/抗HBe血清转换率联合组为52.00 % ,LAM组为45.00 %。丙氨酸氨基转移酶(ALT)复常率,联合治疗组为92.00% ,LAM组为84.00%。治疗结束一年后 ,HBVDNA阴转率 ,联合治疗组为80.00 % ,LAM组为40.00%。HBeAg/抗HBe血清转换率 ,联合治疗组为44.00 % ,LAM组为14.00 %。ALT复常率 ,联合治疗组为76.00% ,LAM组为36.00%。结论联合治疗组对HBVDNA抑制作用、HBeAg/抗HBe血清转换率、ALT复常率,与LAM组比较近期疗效相仿 ,远期疗效高于LAM组有明显差异性(P<0.01)。Objective To assess the short-term and long-term therapeutic efficacy of LAMand LAMjoining Lot.levamisole for treating the patients with chronic hepatitis B.Methods100patients of positive HBV DNA and HBeAg were studied and devided into two group ac-cording to the ratio of1:1.Joining group was treated by Lot.Levamisole every3days and LAM100mg per day for twelve months.LAMgroup was only treated by LAM100mg per day for twelve months.HBV DNA,ALT,antigen and antibody of HBV of the patients were tested regularly.Results At the end of treatment,the HBV DNA undetectable rate in joining group was94.00%and LAMgroup was86.00%.HBeAg/Anti-HBe seroconversion rates achieved52.00%,45.00%in joining group and LAM group.ALT normalization occurred92.00%,84.00%in joining group and LAMgroup.One year after treatment,the HBVDNA undetectable rate in joining group was80.00%and LAMgroup was40.00%.HBeAg/Anti-HBe seroconversion rates achieved44.00%,14.00%in joining group and LAMgroup.ALT normalization occurred76.00%,36.00%in joining group and LAMgroup.Conclusion The results showed the effect of the joining group was as good as the LAMgroup in the near future,but the effect of the joining group was better than the LAM group in the far future(P<0.01).

关 键 词：LAM 联合治疗 HBV ALT 血清转换 左旋咪唑搽剂 拉米夫定 DNA 比例 

分 类 号：R512.62[医药卫生—内科学] R521[医药卫生—临床医学]